Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it

Fixed-dose treatment with nipocalimab, an investigational neonatal Fc receptor blocker, lessened disease severity in generalized myasthenia gravis, according to pivotal phase III data presented at